+ Filter
Loading...
Custom Services order now ship next day

Anti-MPL Recombinant Antibody Products

Loading...

Anti-MPL Products

View More Products

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.


Creative Biolabs is at the forefront of providing premium anti-MPL recombinant antibody products, expertly developed to support the intricate research and therapeutic development efforts of our global clientele. These highly specific and potent antibodies are instrumental in driving scientific advancements, enabling researchers to uncover critical insights into MPL's role in immune regulation and various disease pathologies.

MPL: A Pivotal Target for Hematological Disorders and Therapies

The myeloproliferative leukemia protein (MPL) is the receptor for thrombopoietin (TPO), a critical cytokine governing megakaryocyte differentiation and platelet production. Extensive research has unveiled its crucial role in hematopoietic stem cell maintenance and its dysregulation in various hematological disorders. A deeper understanding of MPL signaling is paramount for developing targeted and more efficacious therapies for conditions such as myeloproliferative neoplasms and thrombocytopenias.

Alternative Names

MPL proto-oncogene; thrombopoietin receptor; MPLV; TPOR; C-MPL; CD110; THPOR; THCYT2; TPO receptor.

Background

In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs. TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated.

Protein class

Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Human disease related genes

Predicted location

Intracellular, Membrane (different isoforms)

Single cell type specificity

Group enriched (Erythroid cells, Excitatory neurons, Oligodendrocytes)

Immune cell specificity

Immune cell enhanced (neutrophil)

Cell line specificity

Cell line enriched (HEL)

Interaction

Homodimer (PubMed:25538044). Interacts with ATXN2L.

Molecular function

Receptor

More Types Infomation

Anti-MPL rAb Products

Creative Biolabs proudly presents a diverse array of anti-MPL recombinant antibody products, engineered to deliver exceptional specificity and high binding affinity. Our commitment to advanced recombinant technology ensures unparalleled consistency and purity, which are vital for achieving dependable and repeatable outcomes in demanding research applications. These advanced tools are indispensable for precise target validation, effective drug screening, and robust diagnostic assay development.

Table 1. Featured anti-MPL recombinant antibody products at Creative Biolabs.

Cat. No. Product Name Target Species Host Species Applications
TAB-157CQ Anti-Human MPL Recombinant Antibody (VB22B) Human, Cynomolgus monkey Mouse ELISA, FC
VS3-FY1910 Rabbit Anti-MPL Recombinant Antibody (clone R03-1C9) Human, Mouse, Rat Rabbit IgG WB
HPAB-1580-FY Mouse Anti-MPL Recombinant Antibody (HPAB-1580-FY) Human Mouse IgG WB, FC, ELISA
HPAB-1581-FY Mouse Anti-MPL Recombinant Antibody (HPAB-1581-FY) Human Mouse IgG FC
HPAB-0411-YC Mouse Anti-MPL Recombinant Antibody (HPAB-0411-YC) Human Mouse IgG1, κ FC, ELISA

Creative Quality Control

At Creative Biolabs, our anti-MPL recombinant antibody products undergo rigorous, multi-stage quality control to guarantee their exceptional performance. Utilizing advanced techniques like ELISA, Western Blot, and flow cytometry, we verify antibody specificity, binding affinity, and functionality. This comprehensive quality assurance approach guarantees that our clients always receive the finest quality antibodies, allowing them to generate trustworthy and effective experimental findings.

Fig.1 WB analysis. (Creative Biolabs Original)Fig.1 WB analysis of anti-MPL antibody
(Cat# VS3-FY1910, Creative Biolabs).

Customer Reviews

Excellent
Ve***a
Anti-Human MPL Recombinant Antibody (TAB-534CL)
The anti-MPL recombinant antibody from Creative Biolabs significantly accelerated our research into novel platelet disorders. The specificity and low background we observed were truly impressive, allowing us to obtain clear and conclusive data much faster than anticipated. Their product quality consistently exceeds expectations.
23/Mar/2024
Excellent
Ma***n
Rabbit Anti-MPL Recombinant Antibody (clone R03-1C9) (VS3-FY1910)
We've integrated Creative Biolabs' anti-MPL antibodies into our diagnostic assay development, and the performance has been outstanding. The consistency across batches is remarkable, which is crucial for our validation processes. This reliability has streamlined our workflow and enhanced the overall accuracy of our diagnostic prototypes
17/Jun/2024
Excellent
Ia***n
Human Anti-MPL Recombinant Antibody (TAB-155CQ) (TAB-155CQ)
Creative Biolabs’ technical support, coupled with their high-quality anti-MPL recombinant antibodies, made our drug screening project a success. The antibodies delivered precise and reproducible results, which were vital for identifying promising therapeutic candidates. Their commitment to customer satisfaction is evident in both their products and services.
21/Nov/2025

rAb Production

Our anti-MPL recombinant antibodies are produced using state-of-the-art expression systems and proprietary purification technologies. This advanced manufacturing process ensures high yields of highly purified, functional antibodies, free from common contaminants. Our commitment to cutting-edge production methodologies guarantees products that meet the most demanding research and development specifications.

Featured Anti-MPL Recombinant Antibody Production PlatformsFig.2 Milligram-scale. (Creative Biolabs Original)
Fig.2 Milligram-scale anti-MPL recombinant antibody production.

Fig.3 Gram-scale. (Creative Biolabs Original)Fig.3 Gram-scale anti-MPL recombinant antibody production.

rAb Modalities

Creative Biolabs' anti-MPL recombinant antibody products are available in multiple modalities, offering versatility for a wide array of research applications.

Fig.4 MPL antibody production and modalities. (Creative Biolabs Original)Fig.4 Full-length anti-MPL recombinant antibody production and modalities.

MPL-Targeted Drug Information

Table 2. Public drug targeting MPL.

Company Research phase Classification Condition
Amgen (Originator)
Kyowa Hakko Kirin (Kyowa Kirin)
Kyowa Kirin
Launched - 2008 Fc Fusion Proteins
Polypeptides, from 41 AA
Acute radiation syndrome
Aplastic anemia
Myelotoxicity
Radiation injury
Thrombocythemia
Thrombocytopenia
Thrombocytopenia, immune (Purpura, idiopathic thrombocytopenic)
3SBio (Originator) Launched Polypeptides, from 41 AA
Recombinant proteins
Thrombocytopenia
Thrombocytopenia, immune (Purpura, idiopathic thrombocytopenic)
Bristol-Myers Squibb (Originator)
Genentech (Originator)
Kirin Holdings
Pfizer
Phase II Megakaryocyte Colony-Stimulating Factor (Meg-CSF)
Polypeptides, from 41 AA
Recombinant proteins
Anemia
Neutropenia
Thrombocythemia
Allogene Therapeutics (Originator) Phase I/II Cancer Immunotherapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR)
Chimeric Cytokine Receptor-Modified T Cells (CCR T Cells)
Multiple myeloma
Clover Biopharmaceuticals (Originator) Phase I Fc Fusion Proteins
Polypeptides, from 41 AA
Cytopenia, chemotherapy- or radiotherapy-induced
Daegu Gyeongbuk Institute Sci Technol (Originator)
Inje University (Originator)
Kosin University (Originator)
Preclinical Agonist Antibodies
Fc Fusion Proteins
Polypeptides, from 41 AA
Single-Chain V-Domain Antibody Fragment (scFv)
Thrombocytopenia
Allogene Therapeutics (Originator) Preclinical Cancer Immunotherapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR)
Chimeric Cytokine Receptor-Modified T Cells (CCR T Cells)
Cancer
Allogene Therapeutics (Originator) Preclinical Cancer Immunotherapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR)
Chimeric Cytokine Receptor-Modified T Cells (CCR T Cells)
Cancer
Emory University (Originator) Preclinical Cancer Immunotherapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (First-Generation CAR)
Acute myeloid leukemia
Alexion Pharmaceuticals (Originator) Preclinical Agonist Antibodies Thrombocytopenia
Chugai Pharmaceutical (Originator) Preclinical Monoclonal Antibodies Thrombocytopenia

(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)

Creative Biolabs is dedicated to supporting your scientific endeavors with our premium anti-MPL recombinant antibody products. Please contact us immediately if you would like to learn more or discuss your unique project requirements. Our skilled staff is ready to give customized solutions and thorough assistance for your research requirements.

Go to compare

Go to compare